Pathway Selected in Top 12 Coolest Products of Inc. 500 Fastest-Growing Companies

inc500-logo
Pathway Genomics announced that its breast cancer risk genetic test, BRCATrue, was included in Inc. magazine’s Coolest Products of the Inc. 500. The genetic test was ranked in the top 12 products from 5000 companies across the nation. View the full list here. “We are honored to be included among incredibly innovative products and forward-thinking companies,” said Jim Plante, Pathway Genomics’ founder and CEO. “Our mission is to provide the most accurate and actionable genetic testing results to physicians and their patients.”  

Pathway Genomics Launches Patient Mobile App at ASHG 2014

SAN DIEGO, CAOctober 20, 2014 – Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has released a patient app that allows existing patients to view their genetic results on mobile devices, such as smart phones and tablets. The announcement was made at the 64th Annual Meeting of the American Society of Human Genetics (ASHG) in San Diego, California. “Pathway’s patient app empowers the individual to view their genetic testing results with a push of a button from their mobile device,” said Jim Plante, Pathway Genomics’ founder and CEO. "Patients can now have their genetic testing results accessible at all times."  

Pathway Genomics Announces Commitment to Free the Data Movement at NSGC Conference

FTD_logo3
SAN DIEGO, CASeptember 18, 2014 – Pathway Genomics Corporation, a global clinical genetic testing company, announced today at the National Society of Genetic Counselors’ 33rd Annual Education Conference its commitment to Free the Data, a movement dedicated to open access to genetic data and collaboration through information sharing.  

Pathway Genomics Launches BreastTrue NGS High Risk Breast Cancer Panel with PALB2

breasttrue-header
SAN DIEGO, CASeptember 10. 2014 – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BreastTrueTM High Risk Panel, a next-generation sequencing test with deletion/duplication analysis to detect mutations in seven high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2.  

Susan G. Komen and Pathway Genomics Sign National Agreement

komen_logo
September 9, 2014 | Susan G. Komen, the world's largest breast cancer organization, issued a press release this morning announcing a national partnership agreement with global clinical laboratory Pathway Genomics to fund community breast cancer education and outreach programs in five cities nationwide. The partnership includes funding for education programs and/or sponsorship of Susan G. Komen Race for the Cure® events in San Diego, Los Angeles, Denver and Seattle, along with funding for grants to reach medically underserved women in Washington, D.C., which has the highest death rate from breast cancer of any city in the United States.  

Pathway Genomics an Inc. 500 Fastest-Growing Company

inc-banner
SAN DIEGO, CAAugust 20, 2014Inc. magazine today ranked global genetic testing company Pathway Genomics No. 173, with a three-year growth rate of 2,415.5%, on its 33rd annual Inc. 500|5000, an exclusive ranking of the nation's fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy — America’s independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other well-known names gained early exposure as members of the Inc. 500|5000.  

Pathway Genomics’ Laboratory Director Honorary Speaker at 2014 National Women’s Survivors Convention

survivorville-post
SAN DIEGO, CAAugust 5, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced its laboratory director, Dr. Linda Wasserman, was an honorary speaker at the second annual National Women’s Survivors Convention. Held last week in Nashville, Tennessee, the convention serves as a place for women survivors of cancer to come together over issues surrounding survivorship. The purpose of the convention is to help women re-enter their lives by supporting, educating, and connecting them with other women whose lives have been touched by cancer. This year’s convention hosted more than 800 people affected by cancer.  

Military and Veterans Affairs Advocate Ellen Embrey Joins Pathway Genomics’ Advisory Board

dod

Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board


SAN DIEGO, CAJuly 10, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Ellen Embrey, B.S., has joined its strategic advisory board. Embrey earned a bachelor’s degree from Virginia Tech and was twice awarded the Department of Defense (DOD) Distinguished Civilian Service Award. Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board.  

Pathway Genomics Co-Hosts Fundraiser Benefiting Susan G. Komen

komen-relativity
Event Marks One-Year Anniversary of US Supreme Court Decision to Ban Human Gene Patenting
 

SAN DIEGO, CAJune 17, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, last week co-hosted a fundraiser benefiting Susan G. Komen. Jim Plante, founder and CEO of Pathway Genomics, and Ryan Kavanaugh, CEO of Relativity, were the hosts of the event, titled Pathway to the Cure. The fundraiser, held in Santa Monica, California, raised more than $300,000 through generous donations made by attendees of the event.

 

Pathway Genomics Responds to Myriad Genetics Lawsuit, Defends the Rights of All Women to Receive BRCA Testing Regardless of Socioeconomic Status

pathway-myriad
Pathway Genomics today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.